Observational studyThe British journal of radiology2022
PET/MR in recurrent glioblastoma patients treated with regorafenib: [
Observational study in The British journal of radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Beyond morphology: imaging the glioblastoma microenvironment in the era of quantitative neuro-oncology.Frontiers in medicine · 2026Review
- The current state of imaging biomarker development and evaluation.The British journal of radiology · 2025Review
- Advances and challenges in precision imaging.The Lancet. Oncology · 2025Review
- Recurrence Patterns after Radiotherapy for Glioblastoma with [(11)C]methionine Positron Emission Tomography-Guided Irradiation for Target Volume Optimization.Diagnostics (Basel, Switzerland) · 2024Article
- [European journal of nuclear medicine and molecular imaging · 2024Article
- Magnetic resonance imaging-derived parameters to predict response to regorafenib in recurrent glioblastoma.Neuroradiology · 2023Article
- Review
- Multimodal imaging findings in patients with glioblastoma with extensive coagulative necrosis related to regorafenib.Neuro-oncology · 2023Article
- Clinical Applications of TSPO PET for Glioma Imaging: Current Evidence and Future Perspective-A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
- Amino Acid Tracer PET MRI in Glioma Management: What a Neuroradiologist Needs to Know.AJNR. American journal of neuroradiology · 2023Review
- Molecular and functional imaging in cancer-targeted therapy: current applications and future directions.Signal transduction and targeted therapy · 2023Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe use of regorafenib in recurrent glioblastoma patients has been recently approved by the Italian Medicines Agency (AIFA) and added to the National Comprehensive Cancer Network (NCCN) 2020 guidelines as a preferred regimen. Given its complex effects at the molecular level, the most appropriate imaging tools to assess early response to treatment is still a matter of debate. Diffusion-weighted imaging and O-(2-
methodsWe retrospectively reviewed 16 consecutive GBM patients who underwent [
resultsPercentage difference in FET volumes correlates with the corresponding percentage difference in ADC (
conclusionIn recurrent glioblastoma patients treated with regorafenib, [ ADVANCES IN KNOWLEDGE: Simultaneous evaluation of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.